Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17512433.2018.1421066PMID 29285947
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intentional overdose of the novel anti-epileptic drug eslicarbazepine presenting with recurrent seizures and ventricular dysrhythmias.

  2018cited by this paper
• Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.

  2018influential reference
• Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study

  2017cited by this paper
• PO045 Perampanel as monotherapy in open-label extension studies

  2017cited by this paper
• Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study

  2017influential reference
• Pooled efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Data from four double‐blind placebo‐controlled pivotal phase III clinical studies

  2017cited by this paper
• Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.

  2017cited by this paper
• Tolerability of new antiepileptic drugs: a network meta-analysis

  2017cited by this paper
• EARLY‐ESLI study: Long‐term experience with eslicarbazepine acetate after first monotherapy failure

  2017cited by this paper
• Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.

  2017cited by this paper
• Eslicarbazepine acetate as a therapeutic option in a patient with carbamazepine-induced rash and HLA-A*31:01.

  2017cited by this paper
• The Burden of Severely Drug-Refractory Epilepsy: A Comparative Longitudinal Evaluation of Mortality, Morbidity, Resource Use, and Cost Using German Health Insurance Data

  2017cited by this paper
• Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy

  2017cited by this paper
• Clinical experience with eslicarbazepine acetate in adults with sub-analysis of elderly.

  2017cited by this paper
• Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy : preliminary results

  2017cited by this paper
• Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies

  2017cited by this paper
• Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.

  2017cited by this paper
• Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.

  2017cited by this paper
• Socioeconomic Outcome and Quality of Life in Adults after Status Epilepticus: A Multicenter, Longitudinal, Matched Case–Control Analysis from Germany

  2017cited by this paper
• Methodological issues associated with clinical trials in epilepsy

  2017cited by this paper
• Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience

  2017cited by this paper
• Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.

  2017cited by this paper
• HLA-A*31: 01 and HLA-B*15:02 association with Stevens–Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population

  2017cited by this paper
• Transition from oxcarbazepine to eslicarbazepine acetate: A single center study

  2017cited by this paper
• Switching to eslicarbazepine acetate in patients with epilepsy: a field-practice observation

  2017cited by this paper
• Conversion to eslicarbazepine acetate monotherapy

  2016influential reference
• Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy

  2016cited by this paper
• Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs.

  2016cited by this paper
• Carbamazepine-related antiepileptic drugs for the treatment of epilepsy - a comparative review

  2016cited by this paper
• 2016 Emerging Science Program Schedule

  2016cited by this paper
• Third generation antiepileptic drug monotherapies in adults with epilepsy

  2016cited by this paper
• A common reference-based indirect comparison meta-analysis of eslicarbazepine versus lacosamide as add on treatments for focal epilepsy.

  2016cited by this paper
• Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus

  2016cited by this paper
• Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures

  2016cited by this paper
• Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study

  2015cited by this paper
• Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy

  2015cited by this paper
• A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures

  2015cited by this paper
• Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus

  2015cited by this paper
• Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.

  2015cited by this paper
• Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial‐onset seizures: A randomized historical‐control phase III study based in North America

  2015cited by this paper
• Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate--Expert opinion.

  2015cited by this paper
• Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results☆☆☆

  2014cited by this paper
• Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures

  2014cited by this paper
• Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial

  2014influential reference
• Eslicarbazepine acetate: an update on efficacy and safety in epilepsy.

  2014cited by this paper
• Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.

  2014cited by this paper
• Eslicarbazepine Acetate: A Review of Its Use as Adjunctive Therapy in Refractory Partial-Onset Seizures

  2014cited by this paper
• Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study.

  2014cited by this paper
• Recommendations for HLA‐B*15:02 and HLA‐A*31:01 genetic testing to reduce the risk of carbamazepine‐induced hypersensitivity reactions

  2014cited by this paper
• Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results.

  2014cited by this paper
• Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers

  2013cited by this paper
• Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial

  2013cited by this paper
• Enzyme induction with antiepileptic drugs: Cause for concern?

  2013cited by this paper
• Efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Integrated analysis of pooled data from double‐blind phase III clinical studies

  2013cited by this paper
• Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.

  2013cited by this paper
• Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers

  2013cited by this paper
• Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.

  2013cited by this paper
• Pharmacokinetics and drug interactions of eslicarbazepine acetate

  2012cited by this paper
• Pharmacokinetics, Drug Interactions and Exposure-Response Relationship of Eslicarbazepine Acetate in Adult Patients with Partial-Onset Seizures

  2012cited by this paper
• Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.

  2011cited by this paper
• Eslicarbazepine acetate for partial-onset seizures

  2011cited by this paper
• Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.

  2011cited by this paper
• A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy

  2011cited by this paper
• [Abrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate].

  2011cited by this paper
• Abrupter Austausch von retardiertem Oxcarbazepin gegen Eslicarbazepinacetat

  2011influential reference
• Eslicarbazepine acetate (BIA 2-093)

  2011influential reference
• Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.

  2011cited by this paper
• Eslicarbazepine acetate: A novel agent for the adjunctive treatment of epilepsy.

  2010cited by this paper
• Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives

  2010cited by this paper
• Historical control monotherapy design in the treatment of epilepsy

  2010cited by this paper
• Drug interactions involving the new second- and third-generation antiepileptic drugs

  2010cited by this paper
• Antiepileptic Drug Interactions - Principles and Clinical Implications

  2010cited by this paper
• Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.

  2010influential reference
• Long‐term efficacy and safety of eslicarbazepine acetate: Results of a 1‐year open‐label extension study in partial‐onset seizures in adults with epilepsy

  2010cited by this paper
• Eslicarbazepine Acetate

  2009cited by this paper
• Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures

  2009influential reference
• Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions.

  2009cited by this paper
• Eslicarbazepine acetate: a new option for the treatment of focal epilepsy

  2009cited by this paper
• Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study

  2009cited by this paper
• Overnight Transition from Carbamazepine to Oxcarbazepine in Children and Adolescents

  2008cited by this paper
• Pharmacokinetics, Efficacy, and Tolerability of Eslicarbazepine Acetate in Children and Adolescents With Epilepsy

  2008cited by this paper
• Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment

  2008cited by this paper
• [Carbamazepine-induced hyponatremia].

  2007cited by this paper
• Efficacy, safety, and tolerability of oxcarbazepine monotherapy.

  2006cited by this paper
• Treatment With Oxcarbazepine During Pregnancy

  2006influential reference
• Safety of the newer antiepileptic drug oxcarbazepine during pregnancy

  2005influential reference
• Hyponatremia from oxcarbazepine and carbamazepine

  2005cited by this paper
• Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.

  2003cited by this paper
• [Ad hoc change from carbamazepine to oxcarbazepine--effectiveness and tolerance. A retrospective analysis].

  2001cited by this paper
• Induction of Ethinylestradiol and Levonorgestrel Metabolism by Oxcarbazepine in Healthy Women

  1999cited by this paper
• CLINICAL PHARMACOKINETICS OF CARBAMAZEPINE

  1988cited by this paper
• Clinical Pharmacokinetics of Carbamazepine

  1978cited by this paper
• British Journal of Clinical Pharmacology Clinically Relevant Drug Interactions with Antiepileptic Drugs

  year unknowncited by this paper
• Pharmacogenomics and Personalized Medicine Dovepress

  year unknowncited by this paper

• Use of cannabidiol for off-label treatment of patients with refractory focal, genetic generalised and other epilepsies

  2025cites this paper
• A multicenter cohort study on the efficacy, retention, and tolerability of cenobamate in patients with developmental and epileptic encephalopathies

  2025cites this paper
• Eslicarbazepine, a third-generation anti-seizure medication, inhibits INa but stimulates IK(M).

  2025cites this paper
• Post-marketing Experience with Cenobamate in the Treatment of Focal Epilepsies: A Multicentre Cohort Study

  2025cites this paper
• Overnight switch from carbamazepine to eslicarbazepine in a real-life clinical scenario: a retrospective study

  2024cites this paper
• Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy

  2023cites this paper
• Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam in the long-term care setting in the USA.

  2022cites this paper
• Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives

  2021cites this paper
• Experience with Eslicarbazepine Acetate Treatment at a Pediatric Epilepsy Center

  2020cites this paper
• The tolerability and safety profile of eslicarbazepine acetate in neurological disorders.

  2020cites this paper
• Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review

  2020cites this paper
• Eslicarbazepine Acetate: A Review in Focal-Onset Seizures

  2020cites this paper
• Effects of eslicarbazepine as add-on therapy on sleep architecture in temporal lobe epilepsy: results from "Esleep" study.

  2020cites this paper
• Levetiracetam-induced de novo psychosis: is there a type of patient with epilepsy who is neurostructurally and/or biologically more vulnerable to developing it?

  2020cites this paper
• Medikamentöse Therapie von epileptischen Anfällen und Epilepsien

  2019cites this paper
• Levetiracetam-induced de novo psychosis: Is there a type of patient with epilepsy who is neurostructural and/or biologically more vulnerable to developing it?

  2019cites this paper
• Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus

  2019cites this paper
• Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus

  2018cites this paper
• Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany

  2018cites this paper